Syndax Pharmaceuticals Inc
SNDXNasdaqCIK 1395937HealthcareFiscal year ends Dec 31
Reports and events: 182 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0416:04 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-332750 |
| 2026-08-0416:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332736 |
| 2026-07-1408:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-302608 |
| 2026-06-1017:04 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-266027 |
| 2026-06-1016:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-265852 |
| 2026-06-0407:16 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-256458 |
| 2026-04-3017:20 ET | DEF 14A | Proxy statementPeriod 2026-04-30 | 0001193125-26-197859 |
| 2026-04-3016:04 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-197154 |
| 2026-04-3016:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197124 |
| 2026-02-2616:04 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-076536 |
| 2026-02-2616:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076522 |
| 2026-01-1216:36 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001193125-26-010486 |
| 2025-12-1916:30 ET | 8-K | 5.03 Amendment to articles or bylaws | 0001193125-25-326961 |
| 2025-11-0316:04 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-262521 |
| 2025-11-0316:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-262509 |
| 2025-10-2416:40 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250052 |
| 2025-08-0416:05 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-101985 |
| 2025-08-0416:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-101974 |
| 2025-06-2608:54 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-25-090205 |
| 2025-05-1616:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-073555 |
| 2025-05-0516:04 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-063518 |
| 2025-05-0516:02 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-063514 |
| 2025-04-0116:01 ET | DEF 14A | Proxy statementPeriod 2025-04-01 | 0000950170-25-048472 |
| 2025-03-0307:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-030394 |
| 2025-03-0307:02 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-030392 |
| 2024-12-2017:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-139121 |
| 2024-11-1817:41 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-127708 |
| 2024-11-1207:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-124545 |
| 2024-11-0516:03 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-121439 |
| 2024-11-0516:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-121437 |
| 2024-11-0416:05 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-24-120673 |
| 2024-08-0116:04 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-089241 |
| 2024-08-0116:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-089235 |
| 2024-05-1516:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-060462 |
| 2024-05-0807:04 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-055053 |
| 2024-05-0807:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055052 |
| 2024-04-0216:00 ET | DEF 14A | Proxy statementPeriod 2024-03-27 | 0000950170-24-040099 |
| 2024-03-1807:10 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-032514 |
| 2024-02-2716:33 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-021253 |
| 2024-02-2716:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-021086 |
| 2023-12-2008:40 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-071749 |
| 2023-12-1517:29 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-23-296814 |
| 2023-12-1216:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-069683 |
| 2023-11-0216:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-058165 |
| 2023-11-0216:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-058156 |
| 2023-10-0207:04 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-050922 |
| 2023-08-0316:06 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037943 |
| 2023-08-0316:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-037936 |
| 2023-07-2407:07 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-033937 |
| 2023-05-2616:47 ET | 8-K | 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-024544 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 19:11 ET. Listed shows no prices and gives no investment advice.